Department of Dermatology, St George Hospital, Sydney, Australia.
J Am Acad Dermatol. 2011 May;64(5):903-8. doi: 10.1016/j.jaad.2010.04.039. Epub 2011 Feb 25.
A range of interventions has been described for the treatment of pemphigus; however, the optimal therapeutic strategy has not been established.
We sought to evaluate the safety and efficacy of interventions for pemphigus vulgaris and pemphigus foliaceus.
We undertook a systematic review and meta-analysis according to the methodology of the Cochrane Collaboration. We selected randomized controlled trials including participants with the diagnosis of pemphigus vulgaris or pemphigus foliaceus confirmed with clinical, histopathological, and immunofluorescence criteria. All interventions were considered. Primary outcomes studied were remission and mortality. Secondary outcomes included disease control, relapse, pemphigus severity score, time to disease control, cumulative glucocorticoid dose, serum antibody titers, adverse events, and quality of life.
Eleven studies with a total of 404 participants were identified. Interventions assessed included prednisolone dose regimen, pulsed dexamethasone, azathioprine, cyclophosphamide, cyclosporine, dapsone, mycophenolate, plasma exchange, topical epidermal growth factor, and traditional Chinese medicine. We found some interventions to be superior for certain outcomes, although we were unable to conclude which treatments are superior overall.
Many interventions for pemphigus have not been evaluated in controlled trials. All studies were insufficiently powered to establish definitive results.
There is inadequate evidence available at present to ascertain the optimal therapy for pemphigus vulgaris and pemphigus foliaceus. Further randomized controlled trials are required.
已经描述了一系列用于治疗天疱疮的干预措施;然而,尚未确定最佳的治疗策略。
我们旨在评估天疱疮和类天疱疮的干预措施的安全性和疗效。
我们根据 Cochrane 协作组织的方法进行了系统评价和荟萃分析。我们选择了随机对照试验,纳入了经临床、组织病理学和免疫荧光标准确诊为天疱疮或类天疱疮的参与者。考虑了所有干预措施。主要结局研究是缓解和死亡率。次要结局包括疾病控制、复发、天疱疮严重程度评分、疾病控制时间、累积糖皮质激素剂量、血清抗体滴度、不良事件和生活质量。
确定了 11 项研究,共 404 名参与者。评估的干预措施包括泼尼松剂量方案、脉冲地塞米松、硫唑嘌呤、环磷酰胺、环孢素、达普司酮、霉酚酸酯、血浆置换、局部表皮生长因子和中药。我们发现某些干预措施在某些结局上更优,但我们无法确定哪种治疗总体上更优。
许多天疱疮的干预措施尚未在对照试验中进行评估。所有研究的效力都不足以确定明确的结果。
目前尚无确定天疱疮和类天疱疮最佳治疗方法的充分证据。需要进一步的随机对照试验。